Purpose
Motion management is critical for the efficacy of carbon ion therapy for moving targets such as lung tumors. We evaluated the feasibility of using four‐dimensional cone beam computed tomography (4D‐CBCT) reconstructed by Simultaneous Motion Estimation and Image Reconstruction (SMEIR) for dose calculation and accumulation in carbon ion treatment of lung cancer.
Methods
Motion‐compensated 4D‐CBCT images were reconstructed with the SMEIR algorithm to capture the most updated anatomy and motion with an updated interphase motion model on the treatment day. Projections of all CBCT phases were simulated from the planning 4D‐CT by the ray tracing technique. Treatment planning and dose calculation were performed with a GPU‐based Monte Carlo dose calculation software for carbon ion therapy. The treatment plan was optimized on the average computed tomography (CT) to obtain optimal intensity of the carbon ions. From the optimized plan, dose distributions on individual phases of 4D‐CT and 4D‐CBCT were calculated by the Monte Carlo‐based dose engine. Dose accumulation was performed on 4D‐CBCT images using deformable vector fields (DVF) generated by SMEIR. The accumulated planning target volume (PTV) dose based on 4D‐CBCT was then compared to the accumulated dose calculated on 4D‐CT, where the DVFs between different phases were obtained by the demons deformable registration algorithm.
Results
Dose value histograms (DVH) as well as absolute deviations of the maximum dose (ΔDmax), mean dose (ΔDmean), and dose coverage metrics (ΔV95% and ΔV100%) for PTV were quantitatively evaluated for the two sets of plans. Good agreement was found between the 4D‐CT and 4D‐CBCT‐based PTV‐DVH curves. The average values of ΔDmax, ΔDmean,ΔV95%, and ΔV100% calculated between the 4D‐CT and SMEIR‐4D‐CBCT‐based plans were 1.91%, 3.55%, 2.12%, and 1.15%, respectively, for the PTVs of ten patient case studies.
Conclusions
Based on these results, SMEIR‐reconstructed 4D‐CBCTs can potentially be used for motion estimation, dose evaluation, and adaptive treatment planning in lung cancer carbon ion therapy.